Autolus Therapeutics plc
AUTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.23 | 0.06 | 0.09 |
| FCF Yield | -40.21% | -13.98% | -68.23% | -33.87% |
| EV / EBITDA | -1.82 | -5.96 | 1.34 | -0.99 |
| Quality | ||||
| ROIC | -33.30% | -53.53% | -31.83% | -36.80% |
| Gross Margin | -1,293.48% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.93 | 0.70 | 0.75 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.78% | 4.06% | 53.43% | 1,146,392.15% |
| Free Cash Flow Growth | -53.98% | -27.14% | 2.82% | 4.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.75 | 1.19 | 2.71 | 1.83 |
| Interest Coverage | -25.98 | -3.99 | -16.05 | -127.04 |
| Efficiency | ||||
| Inventory Turnover | 34.08 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,745.50 | 225.06 | 1,707.50 | 16.47 |